CoChat

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

Leyland, Rebecca, Watkins, Amanda, Mulgrew, Kathy A., Holoweckyj, Nicholas, Bamber, Lisa, Tigue, Natalie J., Offer, Emily, Andrews, John, Yan, Li, Mullins, Stefanie, Oberst, Michael D., Coates Ulrichsen, Jane, Leinster, David A., McGlinchey, Kelly, Young, Lesley, Morrow, Michelle, Hammond, Scott A., Mallinder, Philip, Herath, Athula, Leow, Ching Ching, Wilkinson, Robert W., Stewart, Ross · 2017 · Clinical Cancer Research
Cited by 52

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: To generate and characterize a murine GITR ligand fusion protein (mGITRL-FP) designed to maximize valency and the potential to agonize the GITR receptor for cancer immunotherapy. Experimental Design: The EC50 value of the mGITRL-FP was compared with an anti-GITR antibody in an in vitro agonistic cell–based reporter assay. We assessed the impact of dose, schedule, and Fc isotype on antitumor activity and T-cell modulation in the CT26 tumor model. The activity of the mGITRL-FP was compared with an agonistic murine OX40L-FP targeting OX40, in CT26 and B16F10-Luc2 tumor models. Combination of the mGITRL-FP with antibodies targeting PD-L1, PD-1, or CTLA-4 was analyzed in mice bearing CT26 tumors. Results: The mGITRL-FP had an almost 50-fold higher EC50 value compared with an anti-murine GITR antibody. Treatment of CT26 tumor-bearing mice with mGITRL-FP–mediated significant antitumor activity that was dependent on isotype, dose, and duration of exposure. The antitumor activity could be correlated with the increased proliferation of peripheral CD8+ and CD4+ T cells and a significant decrease in the frequency of intratumoral Tregs. The combination of mGITRL-FP with mOX40L-FP or checkpoint inhibitor antagonists enhanced antitumor immunity above that of monotherapy treatment. Conclusions: These results suggest that therapeutically targeting GITR represents a unique approach to cancer immunotherapy and suggests that a multimeric fusion protein may provide increased agonistic potential versus an antibody. In addition, these data provide, for the first time, early proof of concept for the potential combination of GITR targeting agents with OX40 agonists and PD-L1 antagonists. Clin Cancer Res; 23(13); 3416–27. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2000

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 52

Metadata

Authors
Leyland, R., Watkins, A., Mulgrew, K. A., Holoweckyj, N., Bamber, L., Tigue, N. J., Offer, E., Andrews, J., Yan, L., Mullins, S., Oberst, M. D., Coates Ulrichsen, J., Leinster, D. A., McGlinchey, K., Young, L., Morrow, M., Hammond, S. A., Mallinder, P., Herath, A., Leow, C. C., Wilkinson, R. W., & Stewart, R.
Venue
Clinical Cancer Research
Published
2017-07-01
Volume
23
Issue
13
Pages
3416-3427
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2569297957
Cited by
52
References
2
FWCI
3.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2000
The paper
Leyland, R., Watkins, A., Mulgrew, K. A., Holoweckyj, N., Bamber, L., Tigue, N. J., Offer, E., Andrews, J., Yan, L., Mullins, S., Oberst, M. D., Coates Ulrichsen, J., Leinster, D. A., McGlinchey, K., Young, L., Morrow, M., Hammond, S. A., Mallinder, P., Herath, A., . . . Stewart, R. (2017). A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.